Acuren Corporation Confirms Date for Fourth Quarter and Full Year 2024 Earnings Release
Webcast and Conference Call:
Acuren will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday March 27, 2025. Participants on the call will include Talman Pizzey, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Co-Chairman.
Additionally, a slide presentation will accompany the conference call.
To listen to the call by telephone, please dial 877-407-0789 or 201-689-8562. You may also attend and view the presentation (live or by replay) via webcast by accessing the following URL:
https://viavid.webcasts.com/starthere.jsp?ei=1712055&tp_key=ca6885c47a
A replay of the call will be available shortly after the completion of the live call/webcast via the webcast link above.
About Acuren:
Acuren is a leading provider of critical asset integrity services. The company operates primarily in North America serving a broad range of industrial markets. It provides these essential and often compliance-mandated services in the industrial space and is focused on the recuring maintenance needs of its customers. The work Acuren does fits in the service category referred to as Testing, Inspection, Certification and Compliance (TICC) including Nondestructive Testing (NDT) in the field and the laboratory and in-lab destructive testing capabilities. More information can be found at https://www.acuren.com/.
Forward-Looking Statements
In this press release the Company may discuss events or results that have not yet occurred or been realized, commonly referred to as forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of Acuren Corporation. Such discussion and statements may contain words such as "expect," "anticipate," "will," "should," "believe," "intend," "plan," "estimate," "predict," "seek," "continue," "pro forma" "outlook," "may," "might," "should," "can have," "have," "likely," "potential," "target," "indicative," "illustrative," and variations of such words and similar expressions, and relate in this press release, without limitation, to statements, beliefs, projections and expectations about future events, including, the Company's expectations regarding the release of its financial statements and timing of its earnings conference call. These statements are not guarantees and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements included in this press release speak only as of the date hereof and, except as required by applicable law, the Company does not undertake any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324751848/en/
Contacts
Investor Relations Inquiries:
Dan Scott / Rodny Nacier, ICR Inc.IR@acuren.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
BUTLER NATIONAL CORPORATION REPURCHASES 2.41 MILLION SHARES
Corporation Establishes New Stock Repurchase Program and Closes 2016 Program NEW CENTURY, Kan., Aug. 13, 2025 /PRNewswire/ -- Butler National Corporation (OTCQX: BUKS), a leader in the growing global market for aircraft modification, maintenance, repair and overhaul and a recognized provider of gaming management services, announces that the Company has repurchased 2.41 million of its outstanding shares of common stock since April 30, 2025. The average price paid per share repurchased since April 30, 2025 was $1.51. As a result, the Company closed its 2016 Stock Repurchase Program and established a new $5 million 2025 Stock Repurchase Program that is authorized through April 2027. At current market prices, after giving effect to these recent transactions, this represents authorization to repurchase approximately 4.8% of 64,854,736 outstanding shares. "The Butler National Board of Directors has made stock repurchases a priority. Management has worked diligently to repurchase Butler National common stock through private transactions when larger amounts of shares become available," commented Jeffrey D. Yowell, Executive Chairman. "The new Stock Repurchase Program reflects the commitment of our Board of Directors to enhancing shareholder value and our confidence in Butler National's long-term growth prospects," concluded Mr. Yowell. For the 2.41 million shares repurchased, as of the end of the first quarter on July 31, 2025, the Company had paid the sellers $2.9 million and had remaining payment obligations of $0.9 million due before December 31, 2025. Under the program, Butler National Corporation plans to repurchase shares of its common stock in open market and privately negotiated transactions in accordance with federal securities laws. Management will determine the actual timing, number and value of the shares repurchased under the program, which will depend on a number of factors, including the price of the common stock, general market and economic conditions and applicable legal requirements. About Butler National Corporation Butler National Corporation operates in the Aerospace and Professional Services business segments. The Aerospace Products segment includes the design, manufacture, sale and service of structural modifications, design, integration and installation of electronic equipment, systems and technologies that enhance aircraft operations, and the design, manufacture and sale of defense related articles. Additionally, we operate Federal Aviation Administration (the "FAA") Repair Stations. Companies in Aerospace Products concentrate on products and services for Learjet, Textron Beechcraft, King Air, and Textron Cessna turboprop aircraft. Butler National-Tempe designs and manufactures robust electronic controls and cabling. The Professional Services segment includes the management of a gaming and the related dining and entertainment facility in Dodge City, Kansas. Boot Hill Casino and Resort features approximately 500 slot machines, 15 table games and a DraftKings branded sportsbook. See our website: For investor information, contact:David Drewitz, Investor Relationsdavid@ Or email:Mackenzie Giller, Operationsgmiller@ View original content to download multimedia: SOURCE Butler National Corporation
Business Wire
32 minutes ago
- Business Wire
CARMAT Provides an Update on the Ongoing Receivership Procedure
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today provides an update on the ongoing receivership procedure and announces the suspension of trading in CARMAT shares, starting August 14, 2025, before stock market opening, ahead of the court hearing scheduled on August 19, 2025. Update on the ongoing receivership procedure Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, the judiciary administrator had received, by the deadline of July 31, 2025, one takeover bid within the context of a sales plan (the 'Bid') 1. This Bid will be assessed by the Versailles Economic Court 2 (the "Court") at a hearing scheduled on August 19, 2025. The Company again draws attention to the fact that there is no guarantee at this stage that this Bid will be successful. The Company also reminds that even if the Bid is validated by the Court, the Company's shareholders and creditors may incur a significant loss of up to the total value of their investment or receivables. CARMAT is subject to a risk of liquidation, including in the short term. Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR) Ahead of the court hearing scheduled on August 19, 2025, CARMAT has asked Euronext to suspend the trading of its shares starting on August 14, 2025, before the stock market opens. Another press release will be issued by the Company once the outcome of the court hearing is known. In any case, CARMAT endeavors to provide continuous support to patients who currently benefit from its Aeson® artificial heart. ●●● About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company is currently placed in receivership (opened on July 1, 2025) and is facing a risk of liquidation including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). 1 Offre de reprise en plan de cession » (in French). 2 Tribunal des Activités Economiques de Versailles.
Yahoo
40 minutes ago
- Yahoo
Etoiles Capital Group Co., Ltd Announces Closing of Underwriters' Over-Allotment Option in Connection with Initial Public Offering
HONG KONG, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Etoiles Capital Group Co., Ltd (Nasdaq: EFTY), a Hong Kong-based financial services provider, today announced that it closed the sale of an additional 210,000 Class A ordinary shares of the Company, pursuant to the full exercise of the underwriters' over-allotment option granted in connection with the Company's initial public offering ('IPO', together with such over-allotment closing, the 'Offering'), at the IPO price of $4.00 per share, less underwriting discounts. As a result, the Company has raised aggregate gross proceeds of $6,440,000, including the previously announced IPO gross proceeds of $5,600,000, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. Proceeds from the Offering will be used for business expansion, technology infrastructure, strategic marketing, and general corporate purposes. The Offering was conducted on a firm commitment basis. Prime Number Capital, LLC acted as the representative underwriter and sole book- runner for the Offering. Loeb & Loeb LLP acted as the U.S. counsel to the Company, Ogier acted as the Cayman Islands counsel to the Company, and Ye & Associates, P.C. acted as the U.S. counsel to the underwriting syndicate in connection with the Offering. A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission ('SEC') (File Number: 333-287302) and was declared effective by the SEC on August 7, 2025. The Offering was made only by means of a prospectus, forming a part of the registration statement. A final prospectus relating to the Offering was filed with the SEC on August 7, 2025, which may be obtained from Prime Number Capital, LLC, 12 E 49 St, Floor 27, New York, NY 10017, Attention: Shenghui Yang by email at ecm@ or by calling +1(347) 329-1575. In addition, copies of the prospectus relating to the Offering may be obtained via the SEC's website at This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Forward-Looking StatementsCertain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as 'approximates,' 'assesses,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. About Etoiles Capital Group Co., LtdEtoiles Capital Group Co., Ltd (Nasdaq: EFTY) is a Cayman Islands holding company operating through its Hong Kong subsidiary, Etoiles Consultancy Limited. The Company provides comprehensive financial advisory, capital markets services, and integrated solutions—including corporate financing, initial public offering consulting, and investor relations—to clients navigating global capital markets. ContactsIssuer InquiriesEtoiles Capital Group Co., LtdRoom 1109, 11/F, Tai Yau Building181 Johnston Road, Wanchai, Hong KongTel: +852 2398 8699 | Email: ir@ Underwriter InquiriesPrime Number Capital, LLC27F, 12E 49th Street, New York, NY 10017Tel: (347) 329-1575 | Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
